![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 31, 2026
An update on our NCTN grant award, practice-changing multiple myeloma research, a promising new lung cancer study, and highlights from the Comis Translational Science Symposium
July 31, 2026
This trial is evaluating a new immunotherapy approach for patients with high-risk multiple myeloma that has returned after initial treatment
July 31, 2026
ECOG-ACRIN’s Trial Results Summaries Project informs clinical trial participants of study findings, recognizes their vital contributions, and fosters a spirit of partnership in cancer research
July 31, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
July 31, 2026
The latest findings in breast cancer, cardiotoxicity, leukemia, lung cancer, myeloma, NCI-MATCH, and smoking cessation support during cancer treatment
July 31, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more